 Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, is pleased to inform that EOC Pharma EOC and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing efti designated as EOC202 in China in metastatic breast cancer. The confirmation follows EOC Pharmas analysis of the recently reported Progression Free Survival PFS data, including subgroup analysis, from Immuteps phase IIb AIPAC study. 